Username Password
S&P 500: 1,317.45 Change: +0.03%
Kalimera
Kalimera
P&P Score: 98.98
Stats
Kalimera IS BEATING THE MARKET TODAY
Points: 38.67 (+0.00)
Accuracy: 80.00%
Annual Return: 5.28% 
(7.22% since 1/14/11)
Average Pick Score: 19.32
About Me
Real name MIKE ANTO
Favorites
Kalimera has no favorites
Groups
Kalimera has no groups
Highlighted Picks
Most Recent  04/25/12
BUY    AIG   $28.95
AMER INTL GROUP INC   -1.85%
Buy - Target $36/S
Most Successful  05/23/11
BUY    SGEN   $20.48
SEATTLE GENETICS INC.   +8.93%
FDA approval of their cancer drug has a great potential.
Least Successful  04/25/12
BUY    AIG   $28.95
AMER INTL GROUP INC   -8.23%
Buy - Target $36/S
Recent Posts
Most Recent Blog Post
Kalimera has no blog posts
Most Recent Comments

Kalimera has no recent comments

Picks

Open
Start Date Ticker Rating Call Time Frame Start Price Today (change) End Price Stock Gain S&P Gain Points End Date Analysis
04/25/2012 AIG Rating: 3 BUY Three to Six Months $33.71 $28.95
(-1.85%)
- -14.12% -5.90% -8.23 view
05/23/2011 SGEN Rating: 3 BUY Week or Less $18.80 $20.48
(-0.53%)
- +8.94% +0.01% +8.93 view
01/13/2011 ACAS Rating: 2 BUY Week to a Month $8.39 $9.16
(-0.23%)
- +9.18% +2.62% +6.55 view
Closed
Start Date Ticker Rating Call Time Frame Start Price Today (change) End Price Stock Gain S&P Gain Points End Date Analysis
06/02/2011 EXK Rating: 5 BUY Week or Less $9.55 - $11.55 +20.94% -3.94% +24.88 2011-12-07 00:09:49 view
01/27/2011 OREX Rating: 1 SELL Week or Less $8.74 - $3.16 -63.84% +1.03% +64.44 2011-06-02 12:13:46 view
All
Start Date Ticker Rating Call Time Frame Start Price Today (change) End Price Stock Gain S&P Gain Points End Date Analysis
04/25/2012 AIG Rating: 3 BUY Three to Six Months $33.71 $28.95
(-1.85%)
- -14.12% -5.90% -8.23 view
06/02/2011 EXK Rating: 5 BUY Week or Less $9.55 - $11.55 +20.94% -3.94% +24.88 2011-12-07 00:09:49 view
05/23/2011 SGEN Rating: 3 BUY Week or Less $18.80 $20.48
(-0.53%)
- +8.94% +0.01% +8.93 view
01/27/2011 OREX Rating: 1 SELL Week or Less $8.74 - $3.16 -63.84% +1.03% +64.44 2011-06-02 12:13:46 view
01/13/2011 ACAS Rating: 2 BUY Week to a Month $8.39 $9.16
(-0.23%)
- +9.18% +2.62% +6.55 view
Commentary
BUY: AMER INTL GROUP INC (AIG) Rating: 3
Start Price: $33.71
Points: -8.23
Created: 04/25/2012
Buy - Target $36/S

Comments: 0 | Comment

Recs:
 
BUY: ENDEAVOUR SILVER CORP (EXK) Rating: 5
Start Price: $9.55
Points: +24.88
Created: 06/02/2011
Industry has a great demand for silver

Comments: 1 | Comment

Recs:
 
BUY: SEATTLE GENETICS INC. (SGEN) Rating: 3
Start Price: $18.80
Points: +8.93
Created: 05/23/2011
FDA approval of their cancer drug has a great potential.

Comments: 5 | Comment

Recs:
 
SELL: OREXIGEN THERAPEUTICS INC (OREX) Rating: 1
Start Price: $8.74
Points: +64.44
Created: 01/27/2011
FDA will request additional tests

Comments: 5 | Comment

Recs:
 
BUY: AMERICAN CAPITAL STRATEGIES LTD. (ACAS) Rating: 2
Start Price: $8.39
Points: +6.55
Created: 01/13/2011
It is an undervalue stock with the growth that will propel the price to $12

Comments: 5 | Comment

Recs:
 
Sponsored Links